Resource utilization and cost-effectiveness of counselor- vs. provider-based rapid point-of-care HIV screening in the emergency department

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Walensky, Rochelle P ^a,b,c   Morris, Bethany L ^a   Reichmann, William M ^b,e   da Paltiel, A ^d   Arbelaez, Christian ^b   Donnell Fink, Laurel ^b   Katz, Jeffrey N ^b   Losina, Elena ^b,c,e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COUNSELOR BASED PROGRAM; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH CARE UTILIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MEDICAL STAFF; OVERALL SURVIVAL; POINT OF CARE TESTING; PREVALENCE; PROVIDER BASED PROGRAM; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY AND SPECIFICITY; BIOLOGICAL MODEL; COST BENEFIT ANALYSIS; COUNSELING; ECONOMICS; EMERGENCY HEALTH SERVICE; HEALTH CARE PLANNING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL INFORMATION SYSTEM; MASS SCREENING; MIDDLE AGED; UTILIZATION REVIEW;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; COUNSELING; EMERGENCY SERVICE, HOSPITAL; FEMALE; HEALTH PERSONNEL; HEALTH RESOURCES; HIV INFECTIONS; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; MODELS, BIOLOGICAL; POINT-OF-CARE SYSTEMS; SENSITIVITY AND SPECIFICITY;

EID: 80054007700     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025575     Document Type: Article

References (53)

1. Branson B, Handsfield H, Lampe M, Janssen R, Taylor A, et al. (2006) Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 55: 1-17.
2. Centers for Disease Control and Prevention (2007) Rapid HIV testing in emergency departments-three U.S. sites, January 2005-March 2006. MMWR Morb Mortal Wkly Rep 56: 597-601.
3. Brown J, Shesser R, Simon G, Bahn M, Czarnogorski M, et al. (2007) Routine HIV screening in the emergency department using the new US Centers for Disease Control and Prevention Guidelines: results from a high-prevalence area. J Acquir Immune Defic Syndr 46: 395-401.
4. Haukoos JS, Hopkins E, Conroy AA, Silverman M, Byyny RL, et al. (2010) Routine opt-out rapid HIV screening and detection of HIV infection in emergency department patients. JAMA 304: 284-292.
5. Freedberg KA, Losina E, Weinstein M, Paltiel A, Cohen C, et al. (2001) The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 344: 824-831.
6. Freedberg K, Scharfstein J, Seage GR III, Losina E, Weinstein M, et al. (1998) The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA 279: 130-136.
7. Paltiel AD, Weinstein MC, Kimmel AD, Seage GR III, Losina E, et al. (2005) Expanded screening for HIV in the United States-an analysis of cost-effectiveness. N Engl J Med 352: 586-595.
8. Paltiel AD, Walensky RP, Schackman BR, Seage GR III, Mercincavage LM, et al. (2006) Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med 145: 797-806.
9. Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, et al. (2006) The survival benefits of AIDS treatment in the United States. J Infect Dis 194: 11-19.
10. Walensky RP, Reichmann WM, Arbelaez C, Wright E, Katz JN, et al. (2011) Counselor- versus provider-based HIV screening in the emergency department: results from the universal screening for HIV infection in the emergency room (USHER) randomized controlled trial. Ann Emerg Med 58 (Suppl 1): S126-S132 e124.
11. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. (1996) Cost Effectiveness in Health and Medicine New York Oxford University Press.
12. Department of Health and Human Services (2011) Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. January 10, 2011. Available: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 2011 Jul 27.
13. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, et al. (2009) Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 58: 1-207.
14. Mellors JW, Muñoz A, Giorgi JV, Margolick JB, Tassoni CJ, et al. (1997) Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 126: 946-954.
15. National Technical Information Service (1995) Multicenter AIDS Cohort Study (MACS) Public Dataset: Release P04. Springfield, VA.
16. Texas Department of State Health Services (2005) Texas Vital Statistics: Life Tables Texas Department of State Health Services.
17. Arias E, (2007) United States Life Tables, 2004. pp. 1-40 National Vital Statistics Reports, Centers for Disease Control and Prevention.
18. Losina E, Schackman BR, Sadownik SN, Gebo KA, Walensky RP, et al. (2009) Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis 49: 1570-1578.
19. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, et al. (2006) Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 354: 251-260.
20. Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, et al. (2007) Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 369: 1261-1269.
21. Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, et al. (2005) Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 19: 685-694.
22. Johnson MA, Gathe JC Jr, Podzamczer D, Molina JM, Naylor CT, et al. (2006) A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr 43: 153-160.
23. Lalezari J, Goodrich J, DeJesus E, Lampiris H, Gulick R, et al. (2007) Efficacy and safety of maraviroc plus optimized background therapy in viremic ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results of a phase 2b/3 study in the US and Canada. In: 14th Conference on Retroviruses and Opportunistic Infections. February 25-28, 2007; Los Angeles, CA. February 25-28, 2007.
24. Nelson M, Arasteh K, Clotet B, Cooper DA, Henry K, et al. (2005) Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 40: 404-412.
25. Pozniak AL, Gallant JE, DeJesus E, Arribas JR, Gazzard B, et al. (2006) Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes-a 96-week analysis. J Acquir Immune Defic Syndr 43: 535-540.
26. Arbelaez C, Block B, Losina E, Wright E, Reichmann W, et al. (2009) Rapid HIV testing program implementation: lessons from the emergency department. Int J Emerg Med 2: 187-194.
27. Arbelaez C, Wright E, Losina E, Millen J, Kimmel S, et al. (2009) Emergency provider attitudes and barriers to universal HIV testing in the emergency department. J Emerg Med In press.
28. Pisculli ML, Reichmann WM, Losina E, Donnell-Fink LA, Arbelaez C, et al. (2011) Factors associated with refusal of rapid HIV testing in an emergency department. AIDS Behav 15: 734-742.
29. Walensky RP, Arbelaez C, Reichmann WM, Walls RM, Katz JN, et al. (2008) Revising expectations from rapid HIV tests in the emergency department. Ann Intern Med 149: 153-160.
30. 2009 Red Book (2009) Red Book Montvale, NJ Thomson Reuters.
31. Samet JH, Freedberg KA, Savetsky JB, Sullivan LM, Stein MD, (2001) Understanding delay to medical care for HIV infection: the long-term non-presenter. AIDS 15: 77-85.
32. Ekwueme D, Pinkerton S, Holtgrave D, Branson B, (2003) Cost comparison of three HIV counseling and testing technologies. Am J Prev Med 25: 112-121.
33. Farnham P, Gorsky R, Holtgrave D, Jones W, Guinan M, (1996) Counseling and testing for HIV prevention: costs, effects, and cost-effectiveness of more rapid screening tests. Public Health Rep 111: 44-53.
34. Mylonakis E, Paliou M, Lally M, Flanigan TP, Rich JD, (2000) Laboratory testing for infection with the human immunodeficiency virus: established and novel approaches. Am J Med 109: 568-576.
35. Centers for Disease Control and Prevention (2002) Approval of a new rapid test for HIV antibody. MMWR Morb Mortal Wkly Rep 51: 1051-1052.
36. Association of American Medical Colleges (2008) Faculty Salary Survey Reports. AMMC. Available: https://services.aamc.org/fssreports/general/generalmenu.cfm?current_survey_year=2008. Accessed 2011 May 22.
37. Gebo K, Moore R, Fleishman J, (2003) The HIV Research Network: a unique opportunity for real time clinical utilization analysis in HIV. Hopkins HIV Rep 15: 5-6.
38. Schackman B, Gebo K, Walensky R, Losina E, Muccio T, et al. (2006) The lifetime cost of current human immunodeficiency virus care in the United States. Med Care 44: 990-997.
39. University HealthSystems Consortium (2008) CDP Online Report. Available: www.uhc.edu. Accessed 2011 Jul 27.
40. Centers for Medicare and Medicaid Services (2008) Medicare Physician Fee Schedule. Available: http://www.cms.hhs.gov/physicianfeesched/downloads/RVU08D.zip. Accessed 2011 Jul 27.
41. Bozzette S, Joyce G, McCaffrey D, Leibowitz A, Morton S, et al. (2001) Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med 344: 817-823.
42. WHO (2009) CHOosing interventions that are cost-effective (WHO-CHOICE): Cost-effectiveness thresholds. Geneva: World Health Organization. Available: http://www.who.int/choice/costs/CER_thresholds/en/index.html. Accessed 2011 Jul 27.
43. Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, et al. (2005) Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med 352: 570-585.
44. Walensky RP, Weinstein MC, Kimmel AD, Seage GR III, Losina E, et al. (2005) Routine human immunodeficiency virus testing: an economic evaluation of current guidelines. Am J Med 118: 292-300.
45. Martin EG, Paltiel AD, Walensky RP, Schackman BR, (2010) Expanded HIV screening in the United States: What will it cost government discretionary and entitlement programs? A budget impact analysis. Value Health 13: 893-902.
46. Pinkerton SD, Bogart LM, Howerton D, Snyder S, Becker K, et al. (2010) Cost of rapid HIV testing at 45 U.S. hospitals. AIDS Patient Care STDS 24: 409-413.
47. Irwin K, (2001) Doctors overlook sexual histories too often. AIDS Alert 16: 113-114.
48. Merrill JM, Laux LF, Thornby JI, (1990) Why doctors have difficulty with sex histories. South Med J 83: 613-617.
49. Parish SJ, Clayton AH, (2007) Sexual medicine education: review and commentary. J Sex Med 4: 259-267; quiz 268.
50. Haley N, Maheux B, Rivard M, Gervais A, (2002) Unsafe sex, substance abuse, and domestic violence: how do recently trained obstetricians-gynecologists fare at lifestyle risk assessment and counseling on STD prevention? Prev Med 34: 632-637.
51. George C, (2009) Health Facilities in Houston step up routine testing for HIV. Houston Chronicle. Available: http://www.chron.com/disp/story.mpl/front/6217335.html. Accessed 2011 Jul 28.
52. Bureau of HIV/STD and Viral Hepatitis Prevention (2008) Routine, Opt-Out HIV Screening in Houston, TX. Houston Department of Health and Human Services. Available: http://www.nastad.org/Docs/Public/Resource/2009515_Houston_Fact_Sheet_-_Routine_HIV_Screening_Rev.doc. Accessed 2011 Jul 26.
53. Hewitt P, (2011) EDs reluctant to grow routine HIV testing programs. Ann Emerg Med 57: 16A-18A.